PF-Atlas › Clinical Trials › NCT06559150
A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis
Nebulized Ensifentrine Suspension; 3 mg · Phase 2
Registry ID
NCT06559150
Phase
Phase 2
Status
Recruiting
Drug / intervention
Nebulized Ensifentrine Suspension; 3 mg
Sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Start
2024-09-11
Enrollment
284
Locations
51
About this trial
This study is a randomized, double-blind, placebo-controlled study designed to assess the efficacy and safety of ensifentrine inhalation suspension (3 mg) delivered twice daily via standard jet nebulizer up to 52 weeks, compared to placebo, in participants with non-cystic fibrosis bronchiectasis (NCFBE).
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06559150 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.